Posted On: 09/08/2013 1:26:36 PM
Post# of 57
NVDL'S NitroMist
NitroMist (nitroglycerin lingual aerosol) was approved by the U.S. Food & Drug Administration (FDA) in November 2006 for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. NovaDel is currently finalizing commercialization plans with its North American partner for this important drug.
NitroMist? has a much longer shelf-life than currently available sublingual tablet products and offers the potential benefit of greatly reduced waste due to product expiration.
About Angina pectoris
Angina pectoris is the chest pain or discomfort due to coronary heart disease is typically a symptom of myocardial ischemia. It is estimated that 6 to 10 million Americans suffer from angina (Zaher, et. al. 2004, CDC, 2007). Nitrates are the most common drugs used in patients with angina and patients are instructed to use the drug ether to either treat or prevent an attack.
NitroMist (nitroglycerin lingual aerosol) was approved by the U.S. Food & Drug Administration (FDA) in November 2006 for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. NovaDel is currently finalizing commercialization plans with its North American partner for this important drug.
NitroMist? has a much longer shelf-life than currently available sublingual tablet products and offers the potential benefit of greatly reduced waste due to product expiration.
About Angina pectoris
Angina pectoris is the chest pain or discomfort due to coronary heart disease is typically a symptom of myocardial ischemia. It is estimated that 6 to 10 million Americans suffer from angina (Zaher, et. al. 2004, CDC, 2007). Nitrates are the most common drugs used in patients with angina and patients are instructed to use the drug ether to either treat or prevent an attack.
(0)
(0)
